

**2017 No. 631**

**DANGEROUS DRUGS, ENGLAND AND WALES**

**DANGEROUS DRUGS, SCOTLAND**

**The Misuse of Drugs (Amendment) (England, Wales and  
Scotland) Regulations 2017**

*Made* - - - - - *6th May 2017*

*Coming into force* *31st May 2017*

*To be laid before Parliament*

The Secretary of State makes the following Regulations in exercise of the powers conferred by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 1971(a).

In accordance with section 31(3) of that Act the Secretary of State has consulted with the Advisory Council on the Misuse of Drugs.

**Citation, commencement and extent**

**1.**—(1) These Regulations may be cited as the Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017 and come into force on 31st May 2017.

(2) These Regulations extend to England and Wales and Scotland.

**Amendment of the Misuse of Drugs Regulations 2001**

**2.** The Misuse of Drugs Regulations 2001(b) are amended as follows.

**3.** In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—

(a) before “Bufotenine” insert—

“Adinazolam (1-(8-Chloro-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin-1-yl)-*N,N*-dimethylmethanamine)

*N*-Benzyl-ethylphenidate

Bromazolam (8-bromo-1-methyl-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine”;

---

(a) 1971 c. 38; section 22 was amended by section 177(1) of, and paragraph 12 of Schedule 4, to the Customs and Excise Management Act 1979 (c. 2); other amendments have been made to sections 7, 10 and 31 that are not relevant to these Regulations.

(b) S.I. 2001/3998. Relevant amending instruments are S.I. 2003/1432, 2005/1653, 2005/3372, 2006/986, 2007/2154, 2009/3136, 2010/1144, 2011/448, 2012/385, 2012/1311, 2013/176, 2013/625, 2014/1275, 2014/1377, 2014/3277, 2015/231, 2015/891 and 2016/1125.

- (b) after “Cathinone” insert—
- “4'-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one)
- Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine”);
- (c) after “Concentrate of poppy-straw” insert—
- “Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine)
- 3,4-Dichloroethylphenidate
- 3,4-Dichloromethylphenidate (3,4-DCMP)
- Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one”);
- (d) after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert—
- “Ethylphenidate
- Ethylphenidate”);
- (e) after “Eticyclidine” insert—
- “Etizolam”;
- (f) after “Etryptamine” insert—
- “Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one)
- Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine)
- 4-Fluoroethylphenidate
- 4-Fluoromethylphenidate
- Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one”);
- (g) after “9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[*c*]chromen-1-ol” insert—
- “3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one)
- Isopropylphenidate (IPP or IPPD)”);
- (h) after “Lysergide and other *N*-alkyl derivatives of lysergamide” insert—
- “Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one”);
- (i) after “Methcathinone” insert—
- “4-Methylmethylphenidate
- Methylmorphenate
- Methylnaphthidate (HDMP-28)
- Metizolam (4-(2-Chlorophenyl)-2-ethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine)
- Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one)

Nitrazolam (1-Methyl-8-nitro-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine)

Propylphenidate”;

(j) after “Psilocin” insert—

“Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine)”;

(k) after “3,4-dichloro-*N*-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)” insert—

“3,4-dichloro-*N*-[2-(dimethylamino)cyclohexyl]-*N*-methylbenzamide (U-47,700)”.

Home Office  
6th May 2017

*Sarah Newton*  
Parliamentary Under Secretary of State

### EXPLANATORY NOTE

*(This note is not part of the Regulations)*

These Regulations amend the Misuse of Drugs Regulations 2001 (S.I. 2001/3998) (“the Regulations”). The Schedule of the Regulations in which a controlled drug is placed affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to that drug.

Regulation 3 adds a synthetic opioid (known as U-47,700), several methylphenidate related materials and a number of designer benzodiazepines to Schedule 1 to the Regulations. The controlled drugs placed in Schedule 1 to the Regulations are those subject to the tightest controls.

An impact assessment will be published alongside the Explanatory Memorandum on the [legislation.gov.uk](http://legislation.gov.uk) website.

---

© Crown copyright 2017

Printed and published in the UK by The Stationery Office Limited under the authority and superintendence of Carol Tullo, Controller of Her Majesty’s Stationery Office and Queen’s Printer of Acts of Parliament.

£4.25

UK201705095 05/2017 19585

<http://www.legislation.gov.uk/id/uksi/2017/631>

ISBN 978-0-11-115835-7



9 780111 158357